Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open, Randomized Controlled, Multi-center Phase III Clinical Trial Comparing High-dose Epirubicin and Standard-dose Epirubicin in R±CEOP in Newly Diagnosed Young Patients With Medium/High-risk Diffuse Large B-cell Lymphoma

NCT03151044 is registered in ClinicalTrials.gov with FENG Ji-feng as lead sponsor.

NCT NCT03151044
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03151044 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open, Randomized Controlled, Multi-center Phase III Clinical Trial Comparing High-dose Epirubicin and Standard-dose Epirubicin in R±CEOP in Newly Diagnosed Young Patients With Medium/High-risk Diffuse Large B-cell Lymphoma
Lead sponsor
FENG Ji-feng
Phase
Phase 3
Overall status
Unknown status
Start date
July 31, 2016
Completion date
July 31, 2017
Enrollment
408 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma